Joseph Podojil
Director of Immunology Cour Pharmaceuticals Development Co., Inc.
Dr. Podojil is an investigator that has extensive experience with the analysis of T cell responses, as well as determining the role of Th1 cell, Th17 cell, and regulatory T cell function. His research has focused on determining the cellular and molecular mechanisms underlying the differential effect of both costimulatory and checkpoint inhibitor function.
Seminars
Wednesday 24th March 2027
Preclinical Analyses of Antigen-Specific CNP Function & Crossover to Clinical Findings
9:00 am
- Presentation of cellular and molecular pathways regulating peripheral antigen-specific tolerance
- Presenting alterations in antigen-specific T-cell phenotype and location in the therapeutic setting
- Presenting common measurable changes within blood between preclinical and clinical studies
Thursday 25th March 2027
10 Years of the Antigen-Specific Immune Tolerance Summit Panel Discussion: Assessing this Year’s Presentations & Defining the Next Steps in Immune Tolerance Research for Clinical Success
3:00 pm
- Evaluating the novel mechanistic insights from this year’s program
- Assessing the preclinical data shared and looking to the next year’s clinical therapeutic landscape
- Supercharging antigen-specific immune tolerance therapies to the clinic – what can the field do together to make the promise of the technology a reality?
